"AstraZeneca’s revenues improved over the course of the year, a sign of how our company is steadily turning a corner. Strong commercial execution helped us bring our science to more patients, making the most of our exciting pipeline. We made encouraging progress across the main therapy areas...
AstraZeneca has a deep-rooted heritage in Oncology and offers a quickly growing portfolio of new medicines that has the potential to transform patients’ lives and the Company’s future. With at least six new medicines to be launched between 2014 and 2020 a...
AstraZeneca had other follow-on drugs in the pipeline—namely Nexium, an improvement on the original Prilosec molecule. Additionally, the company had the opportunity to introduce its own version of generic omeprazole, hence becoming the first mover in the generic segment, and/or introduce an OTC ...
“The performance of our new medicines demonstrated the ability of our commercial teams to convert the pipeline into successful medicines,” Soriot said. In addition to those medicines performing well, the company reported that sales in emerging markets were also stronger, growing by 12 perc...
AstraZeneca Strengthens its Cardiovascular Pipeline with Agreement for a Pre-Clinical Novel Lipid-Lowering Therapy October 8, 2024 0 AstraZeneca Agreement with CSPC Pharmaceutical Group Yesterday, October 7, 2024, AstraZeneca (AZN) announced it entered into an exclusive license agreement with CSPC Pha...
"We have more than doubled the number of potential medicines in our late-stage pipeline since 2012 and we are on track to return to growth by 2017," Chief Executive Pascal Soriot said in a statement. "Weare building a sustainable, more durable and profitable company." ...
Ruud Dobber, Ph.D, Executive Vice President and President, BioPharmaceuticals Business Unit,AstraZeneca, said: “Our broad pipeline and portfolio of inhaled and biologic medicines are the cornerstone of our bold ambition to transform respiratory care. COPD remains one of the leading causes of...
Discovery Pipeline Disposables Advisor Downstream ProcessingDownstream ProcessingDownstream ProcessingDownstream ProcessingDownstream Processing Elements of Biopharmaceutical Production From the CEO From the Editor Inside Standards Interphex Keynote Sessions ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturi...
AstraZeneca announced that it has entered into a definitive agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases. The proposed acquisition will bolster the Alexion, AstraZeneca Rare Disease late-st...
NI006 is an ATTR depleter that specifically targets tissue-deposited, misfolded transthyretin, with the potential to treat patients with advanced ATTR-CM. NI006 adds a novel and complementary approach to AstraZeneca and Alexion's pipeline of investigational therapies focused on amyloidosis and strengthe...